Supplemental material
OncoImmunology
Volume 13, 2024 - Issue 1
Original Research
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
Antonio Tapia-Galisteoa Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain;b Cancer Immunotherapy Unit (UNICA), Hospital Universitario 12 de Octubre, Madrid, Spain;c Immuno-oncology and Immunotherapy Group, Biomedical Research Institute Hospital 12 de Octubre, Madrid, Spain;d H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
https://orcid.org/0000-0002-0507-8435View further author information
https://orcid.org/0000-0002-0507-8435View further author information, Iñigo Sánchez-Rodrígueza Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spainhttps://orcid.org/0000-0002-6440-0922View further author information
https://orcid.org/0000-0002-6440-0922View further author information, Javier Narbonae Department of Biochemistry and Molecular Biology, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Madrid, Spainhttps://orcid.org/0000-0002-6118-841XView further author information
https://orcid.org/0000-0002-6118-841XView further author information, Patricia Iglesias-Hernándeza Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spainhttps://orcid.org/0000-0002-0815-3322View further author information
https://orcid.org/0000-0002-0815-3322View further author information, , Anaïs Jiménez-Reinosob Cancer Immunotherapy Unit (UNICA), Hospital Universitario 12 de Octubre, Madrid, Spain;c Immuno-oncology and Immunotherapy Group, Biomedical Research Institute Hospital 12 de Octubre, Madrid, Spain;d H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0001-8229-1881View further author information
https://orcid.org/0000-0001-8229-1881View further author information, Marta Comptef Department of Antibody Engineering, Leadartis SL, Madrid, Spainhttps://orcid.org/0000-0002-7138-9266View further author information
https://orcid.org/0000-0002-7138-9266View further author information, , , Patrick Chamesh Aix Marseille Univ, CNRS, INSERM, Institute Paoli-Calmettes, CRCM, Marseille, Francehttps://orcid.org/0000-0002-6104-6286View further author information
https://orcid.org/0000-0002-6104-6286View further author information, Javier Lacadenae Department of Biochemistry and Molecular Biology, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Madrid, Spainhttps://orcid.org/0000-0002-7314-0333View further author information
https://orcid.org/0000-0002-7314-0333View further author information, Luis Álvarez-Vallinab Cancer Immunotherapy Unit (UNICA), Hospital Universitario 12 de Octubre, Madrid, Spain;c Immuno-oncology and Immunotherapy Group, Biomedical Research Institute Hospital 12 de Octubre, Madrid, Spain;d H12O-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spainhttps://orcid.org/0000-0003-3053-6757View further author information
https://orcid.org/0000-0003-3053-6757View further author information & Laura Sanza Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SpainCorrespondence[email protected]
https://orcid.org/0000-0002-3119-3218View further author information
https://orcid.org/0000-0002-3119-3218View further author information show all